Long-term TAVI durability: what are the yet unanswered questions?

Nicolas Dumonteil and Stefan Blankenberg discuss the long-term durability of transcatheter heart valves and the implications for the future of TAVI.

Reviewing the latest evidence, including the 7-year results from PARTNER 3 and extended follow-up from Evolut Low Risk, they highlight the reassuring outcomes observed for death and stroke compared with surgery.

The discussion also addresses emerging signals related to valve reintervention and the importance of continued surveillance as TAVI is increasingly used in younger and lower-risk patients.

What factors may predict valve deterioration, and what questions remain unanswered regarding long-term durability? This exchange explores the challenges that will shape the next generation of TAVI care.

This interview was filmed at EuroPCR 2026: see more videos here.